Oncologist @PennMedicine @PennCancer specializing in multiple myeloma and cellular immunotherapy.
Philadelphia, PA
Joined July 2014
- Tweets404
- Following597
- Followers812
- Likes422
Al Garfall retweeted
In @BloodAdvances we report on 56 patients with secondary MDS after CAR T cell therapy compared to @Ramikomrokji database of patients with tMN after auto transplant or standard chemo/XRT 🧵
pubmed.ncbi.nlm.nih.gov/4284…
Al Garfall retweeted
The most important briefings of the day.
Karl Deisseroth, professor of bioengineering and of psychiatry and behavioral sciences, shares the news of his Nobel Prize with his kids.
Al Garfall retweeted
Anselamimab was approved in Japan as Amylpave for systemic k-AL on Sept 16th in Japan!
Al Garfall retweeted
Free to read via the Myeloma Collection link during #IMS26 (though Sunday):
aacrjournals.org/bloodcancer…
@AlGarfall
Read this research brief by #IMS26 speakers Rahul Banerjee, Doris Hansen, and Surbhi Sidana, “Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.” aacrjournals.org/bloodcancer… @rahulbanerjeeMD @SurbhiSidanaMD
Al Garfall retweeted
Incredible 2-year PFS with Ramantamig in a ~95% CD38-refractory and 100% triple-class exposed population! These results are substantially superior compared to single-agent BCMA BsAbs and BCMA or GPRC5D CAR Ts in similar population. Based on these results, its plausible that we will see a near-flat PFS curve with Ram in Trilogy-5!
#IMS26
@AlGarfall @MileHighMyeloma
Al Garfall retweeted
Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients [Nov 25, 2021] Mariano Arribas et al. @Rfonsi1 @AjHematology onlinelibrary.wiley.com/doi/… #mmsm #bmtsm #IDonc HT @RahulBanerjeeMD
Al Garfall retweeted
Such an exciting milestone for another groundbreaking RCT in newly diagnosed #myeloma from @CoMMitTrials testing time-limited BsAb therapy to improve outcomes in MRD-positive and de-escalating ASCT in MRD-negative patients after Quad induction! Grateful for the small role we got to play in it @columbiacancer!
This paradigm-challenging trial is 💯 accrued! Congratulations to the sites, investigators, staff and our gratitude to patients. @bhemato @ldandersonjr @nsc_natalie @SusanBal9 @CBCIDocs @rajshekharucms @huntsmanMM @RahulBanerjeeMD @DholariaMD @MMBaljevicMD @End_myeloma
Al Garfall retweeted
Anticd38 are absolutely pivotal in myeloma, the question of how long to use it still remains open, there likely is a sweet spot, glad our trial @CDNCancerTrials @AnnetteHay1 will try to address this @MyelomaCanada
The oncology blockbuster race in 2025: 💊 Keytruda leads at $31.6B, followed by Darzalex at an impressive $14.35B and Opdivo at $10B—remarkably, a #MultipleMyeloma therapy now ranks #2 among the world’s top-selling oncology drugs! 🌎🔥 #Myeloma #Oncology #CancerResearch
Al Garfall retweeted
Expert perspectives. Real-world insights. A must-attend session at #IMS26 ➡️bit.ly/4cdFJkH
Al Garfall retweeted
🚨NEW @BloodPortfolio Why do some CLL-derived CAR T-cell products fail even when they still produce inflammatory cytokines? @jh_noll et al (link in reply) identifies immunosenescence, not exhaustion alone.
-Senescence and Senescence Associate Secretory Phenotype (SASP) programs were detectable before infusion, intensified during manufacturing in susceptible products, and tracked with weak in vivo CAR T-cell expansion and inferior survival.
- Repeated CD19 stimulation exposed a proliferative ceiling, while p53-high products lost cytotoxic reserve. Poor response was also associated with costimulatory loss and reduced TCR diversity.
- Ibrutinib attenuated senescence-associated features and SASP output and improved proliferative fitness. The broader message: starting T-cell fitness is measurable and potentially modifiable.
#immunology #immunotherapy #immunosenescence #TCell #CARTCell #CLL
Al Garfall retweeted
🧵 Myeloma community: CMS is considering an important change to Medicare coverage for autologous stem cell transplant (ASCT). Comments are needed.
CMS proposal + comment submission:
cms.gov/medicare-coverage-da…
@RahulBanerjeeMD @AlGarfall @End_myeloma @SurbhiSidanaMD @DrKrinaPatel
Our experience (N=4, or 1.5% of our pts) with neuralgic amyotrophy leading to arm/shoulder weakness/pain after cilta-cel for #mmsm; improvement with steroids but persistent symptoms in most.
doi.org/10.1002/mus.70358
Al Garfall retweeted
De-escalation in MM: Tough questions—but we now have the tools and drugs to do this in select pts. Here we review existing evidence and offer practical guidance for designing the next wave of de-escalation trials @End_myeloma @Mohty_EBMT @AlGarfall @VincentRK
Al Garfall retweeted
Phase I/II Trial of Evomela for ASCT for MM. Evomela 225 mg/m² improves MRD‑negative CR rates and shows a high probability of longer PFS vs MEL200 #mmsm #bmtsm @UTMDAnderson @DQBMD @BloodPortfolio ashpublications.org/bloodadv…
Al Garfall retweeted
longly awaited data and manuscript on FcRH5 x CD3 TCE in relapsed refractory myeloma. Congrats @CohenAd_MMdoc and @DoctorAKrishnan nature.com/articles/s41591-0…
Al Garfall retweeted
Anti-BCMA TCE in newly diagnosed myeloma. New era is here, end of HCT? congrats @RaabMarc @RascheLeo nature.com/articles/s41591-0…
Al Garfall retweeted
Great point. The relevance of sequencing is predicated on the failure of the first therapy in the sequence. As we move immunotherapy to earlier populations, failure will be minimal, diminishing the hypothetical implications for sequencing.
Al Garfall retweeted
New CAR T treatment opens doors for kidney patients ft. Ali Naji (@PennSurgery), Mary Kaminski, @krjmd (@Penn_Transplant), Vijay Bhoj, @malekkam1, @carlhjune, Nicholas Brown (@PennPathLabMed), Sabiha Hussain (@PennKidney) & @AlGarfall (@PennCancer) tinyurl.com/ykvbx4c4
